First GLP‑1 Pill
- The FDA approved oral semaglutide as the first GLP‑1 pill for weight loss under the Wegovy brand. (ajmc.com) - The approval followed positive Phase III OASIS 4 results showing substantial weight loss and cardiometabolic improvements. (appliedclinicaltrialsonline.com) - Coverage remains uncertain because insurers and Medicare pilots are flagging participation challenges that could limit patient access. (reuters.com)
Glucagon-like peptide-1 drugs copy a gut hormone that slows digestion and lowers appetite; on Tuesday, the Food and Drug Administration cleared Wegovy tablets so patients can take semaglutide for obesity as a pill instead of an injection. (accessdata.fda.gov) The new label says Wegovy tablets are approved with diet and exercise to reduce excess body weight and maintain weight loss in adults with obesity, or adults with overweight plus at least one weight-related condition. The same tablet label also includes a cardiovascular indication for adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) The approval gives Novo Nordisk a second Wegovy form in the U.S. market, alongside the weekly shot. The prescribing information lists both “Wegovy injection” and “Wegovy tablets,” with semaglutide as the active drug in each. (accessdata.fda.gov) The main study behind the pill, OASIS 4, tested 25 milligrams of oral semaglutide once a day in 307 adults without diabetes at 22 sites in four countries. Participants were randomized 2-to-1 to semaglutide or placebo and all received lifestyle counseling. (nejm.org) By week 64, patients taking the pill lost an estimated 13.6% of body weight on average, versus 2.2% with placebo. The semaglutide group was also more likely to hit 5%, 10%, 15%, and 20% weight-loss thresholds, and reported better physical-function scores on a weight-related quality-of-life scale. (nejm.org) The tradeoff looked familiar from other semaglutide drugs: stomach side effects were common. In OASIS 4, gastrointestinal adverse events were reported in 74.0% of patients on oral semaglutide and 42.2% on placebo. (nejm.org) Earlier OASIS data had already suggested the pill could approach the weight loss seen with shots. In OASIS 1, a higher 50-milligram oral dose produced 15.1% average weight loss at 68 weeks in the treatment-policy analysis, versus 2.4% with placebo. (thelancet.com) Access is still the harder question. Reuters reported on April 21 that UnitedHealth told investors there are “challenges” and “outstanding questions” around the Centers for Medicare & Medicaid Services BALANCE model, the pilot meant to expand obesity-drug coverage, and said the insurer was in active talks with the agency. (usnews.com) CMS says Medicaid access under BALANCE can begin as early as May 2026, while Medicare Part D access under the model starts in January 2027. CMS also created a separate “Medicare GLP-1 Bridge” that begins in July 2026 and runs outside the Part D benefit, so Part D sponsors do not carry risk for those drugs during the bridge period. (cms.gov) So the science case for a Wegovy pill is now settled enough for an FDA label, but the market test starts next: whether employers, commercial insurers, Medicaid programs, and Medicare pilots will actually pay for it at scale. (accessdata.fda.gov)
